Nootropics—commonly described as “cognitive enhancers” or “brain health ingredients”—are increasingly being incorporated into functional foods and beverages. From botanical extracts like Bacopa monnieri and Ginkgo biloba to amino acids, lipids, and other bioactive compounds, nootropic ingredients are now appearing in formats such as ready-to-drink beverages, powders, and snack products.
As this shift from supplements to food applications continues, the regulatory landscape becomes more important. In the United States, ingredients added to conventional foods must have a clear safety basis—most often through a Generally Recognized as Safe (GRAS) determination.
For nootropic ingredients, GRAS status is not a blanket designation. Instead, it is assessed on an ingredient-by-ingredient basis, taking into account factors such as identity, manufacturing process, composition, intended use levels, and the quality of available safety data.
As a result, while some nootropic ingredients may be suitable for use in foods under GRAS, others may require additional evaluation—or may be limited to use in dietary supplements depending on their intended applications, regulatory status and history of use.
The term “nootropic” has evolved significantly over time. Originally used to describe substances that enhance memory and cognitive function while maintaining a strong safety profile, it is now applied more broadly across the food, supplement, and pharmaceutical landscapes.
Today, a nootropic generally refers to a substance intended to support cognitive functions such as:
Nootropic ingredients can include:
From a GRAS perspective, this diversity is important—because regulatory eligibility depends heavily on the type of nootropic and its intended use.
Under the Federal Food, Drug, and Cosmetic Act, substances added to food are considered food additives unless they are exempt. GRAS is one of the primary exemptions.
A substance can be considered GRAS if it is:
GRAS status is typically established through:
For most modern nootropic ingredients—especially extracts, isolates, or novel compounds—the scientific procedures pathway is required.
Many nootropic ingredients enter the market through dietary supplements before being considered for food use. However, the regulatory requirements differ significantly.
Dietary supplements:
Conventional foods and beverages:
This distinction is critical: a nootropic ingredient can be marketed legally as a supplement but still require a GRAS determination for use in a beverage, bar, or other conventional food product.
No—nootropic ingredients are not inherently GRAS.
Each nootropic ingredient must be evaluated individually based on:
This is particularly important for nootropic products because:
As a result, the level of safety evidence required for GRAS may increase with ingredient novelty and concentration.
Some ingredients commonly marketed as nootropics already have GRAS status or established use in foods, including:
For botanical nootropics, the situation is more nuanced:
GRAS precedent can be helpful—but it must align with the specific ingredient, manufacturing process, and intended use.
1. Regulatory pathway assessment
Determine whether the ingredient is best suited for:
2. Ingredient characterization
A GRAS determination requires clear and reproducible identity:
3. Safety evaluation
A GRAS conclusion can be supported by:
4. Exposure assessment
Estimated Daily Intake (EDI) must account for:
5. GRAS dossier and expert review
A complete GRAS dossier compiles all data into a structured safety narrative, typically reviewed by a panel of qualified experts and optionally submitted to FDA.
Nootropics represent a fast-growing category within functional foods—but GRAS requirements remain ingredient-specific and evidence-driven.
Key considerations include:
If your company is developing a nootropic ingredient for use in foods or beverages, dicentra’s regulatory and toxicology team can help assess the appropriate pathway, develop a defensible GRAS position, and support regulatory strategy.